ZYME
vs
S&P 500
ZYME
S&P 500
Over the past 12 months, ZYME has significantly outperformed S&P 500, delivering a return of +94% compared to the S&P 500's +13% growth.
Stocks Performance
ZYME vs S&P 500
Performance Gap
ZYME vs S&P 500
Performance By Year
ZYME vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Zymeworks Inc
Glance View
Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.